Project Grant K23HL181314
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $201K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $731,287 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate airway epithelial cell reprogramming mechanisms in chronic lung allograft dysfunction. The research will test whether mTOR signaling drives chronic lung allograft dysfunction through airway epithelial cell reprogramming and examine mTOR as a predictive biomarker of allograft...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $795,464 to The Regents of the University of California, San Francisco on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into adaptive-like natural killer cells in pulmonary cytomegalovirus reactivation. The project investigates whether local cytomegalovirus-specific natural killer cell immune responses in the lungs potentiate...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $744,157 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the molecular mechanisms of lung cell fate determination in the conducting airways and alveolar epithelium. The research investigates how SOX9+ progenitors produce SOX2+ cells to form conducting airways and generate AT1/2 cells to form alveoli, with emphasis on Hippo signaling and...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $778,504 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate molecular mechanisms controlling lung capillary speciation, plasticity, and function during early postnatal development. The research examines how distinct subtypes of lung capillary endothelial cells—CAP1 and CAP2—contribute to alveolar formation and repair after injury during...
- The National Heart, Lung, and Blood Institute awarded New York University a Project Grant of $847,373 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The project will use national organ transplant registry data, including structured clinical data and unstructured narratives describing donor chest imaging findings, to improve evidence for lung offer decisions in transplantation. Large language models will be trained to extract structured data elements from...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,097,760 on February 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund a Project Grant (R35HL183538) investigating mechanisms of age-related pulmonary fibrosis and lung regeneration. The research program addresses idiopathic pulmonary fibrosis (IPF), a progressive disease affecting approximately 200,000 patients annually in the United States with...
- The National Institute of Allergy and Infectious Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $247,500 on July 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a microfluidic assay for detecting neutrophil extracellular traps in bronchoalveolar lavage fluid from lung transplant patients. The project addresses chronic lung allograft dysfunction, a progressive scarring condition that limits survival in lung...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,559,572 on June 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into the multiciliation cycle, a variant cell cycle mechanism that coordinates centriole biogenesis and ciliogenesis in multiciliated cells lining the mammalian airway. Multiciliated cells defend the lungs from inhaled pathogens and particulates but require...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $174,744 on June 2, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the phosphatase SHP1 in modulating acute lung injury and acute respiratory distress syndrome. The research focuses on SHP1-dependent regulation of neutrophil activation and its protective effects against hyperinflammation and pulmonary hemorrhage in acute lung...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $787,297 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 4, 2026. The award funds research into vascular dysfunction and lung allograft health, specifically investigating the mechanisms of primary graft dysfunction (PGD)—an ischemia-reperfusion injury that occurs in approximately 35 percent of lung transplants. The research examines how inflammasome-mediated pyroptosis and endothelial...